ScoreComparison
Why is Citi Pharma Ltd. ?
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.63
2
Healthy long term growth as Net Sales has grown by an annual rate of 280.07% and Operating profit at 191.98%
3
Flat results in Mar 25
- OPERATING CASH FLOW(Y) Lowest at PKR -913.66 MM
- INTEREST(Q) At PKR 99.06 MM has Grown at 45.96%
- DEBT-EQUITY RATIO (HY) Highest at 29.09 %
4
With ROE of 14.9, it has a attractive valuation with a 3.5 Price to Book Value
- Over the past year, while the stock has generated a return of 0%, its profits have risen by 3.1% ; the PEG ratio of the company is 7.7
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Citi Pharma Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Citi Pharma Ltd.
192.37%
3.85
56.83%
Pakistan KSE 100 Share
26.26%
2.81
22.77%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
39.82%
EBIT Growth (5y)
48.67%
EBIT to Interest (avg)
8.63
Debt to EBITDA (avg)
0.27
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
1.53
Tax Ratio
30.09%
Dividend Payout Ratio
89.64%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.56%
ROE (avg)
13.90%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
1.95
EV to EBIT
14.04
EV to EBITDA
12.71
EV to Capital Employed
1.85
EV to Sales
1.71
PEG Ratio
3.39
Dividend Yield
NA
ROCE (Latest)
13.19%
ROE (Latest)
8.21%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
RAW MATERIAL COST(Y)
Fallen by -48.07% (YoY
NET SALES(Q)
Highest at PKR 4,332.57 MM
OPERATING PROFIT(Q)
Highest at PKR 882.95 MM
OPERATING PROFIT MARGIN(Q)
Highest at 20.38 %
PRE-TAX PROFIT(Q)
Highest at PKR 723.69 MM
NET PROFIT(Q)
Highest at PKR 404.33 MM
EPS(Q)
Highest at PKR 1.77
-9What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at PKR -943.91 MM
INTEREST(HY)
At PKR 202.02 MM has Grown at 52.53%
DEBT-EQUITY RATIO
(HY)
Highest at 23.89 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 3.01 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.06 times
Here's what is working for Citi Pharma Ltd.
Net Sales
Highest at PKR 4,332.57 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (PKR MM)
Net Sales
At PKR 4,332.57 MM has Grown at 30.31%
over average net sales of the previous four periods of PKR 3,324.78 MMMOJO Watch
Near term sales trend is positive
Net Sales (PKR MM)
Operating Profit
Highest at PKR 882.95 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (PKR MM)
Operating Profit Margin
Highest at 20.38 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at PKR 723.69 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (PKR MM)
Pre-Tax Profit
At PKR 723.69 MM has Grown at 119.89%
over average net sales of the previous four periods of PKR 329.12 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (PKR MM)
Net Profit
Highest at PKR 404.33 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (PKR MM)
EPS
Highest at PKR 1.77
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (PKR)
Raw Material Cost
Fallen by -48.07% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Citi Pharma Ltd.
Interest
At PKR 202.02 MM has Grown at 52.53%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (PKR MM)
Debt-Equity Ratio
Highest at 23.89 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 3.01 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Operating Cash Flow
Lowest at PKR -943.91 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (PKR MM)
Debtors Turnover Ratio
Lowest at 4.06 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
